Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) will announce its Q3 2022 financial results before the market opens on November 3, 2022. A conference call will be held at 9:00 a.m. ET the same day to discuss these results and key milestones. Participants can access the call via a live webcast or by phone. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently undergoing two Phase 3 clinical trials for hematologic malignancies.

Positive

• Conducting two Phase 3 trials for imetelstat in hematologic malignancies.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 9:00 a.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL%20. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005883/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When will Geron Corporation release its Q3 2022 financial results?

Geron Corporation will release its Q3 2022 financial results on November 3, 2022, before the market opens.

What time is the conference call for Geron's Q3 2022 financial results?

The conference call for Geron's Q3 2022 financial results is scheduled for 9:00 a.m. ET on November 3, 2022.

How can I access Geron's conference call on November 3, 2022?

You can access Geron's conference call via a live webcast on their website or by phone using the provided conference ID.

What is Geron Corporation's focus in its clinical trials?

Geron Corporation is focused on developing imetelstat, a telomerase inhibitor, in two ongoing Phase 3 trials for hematologic malignancies.